bicyclo(2.2.1)heptene: structure in first source
ID Source | ID |
---|---|
PubMed CID | 638051 |
CHEBI ID | 52286 |
MeSH ID | M0299226 |
Synonym |
---|
unii-2q51fls550 |
2q51fls550 , |
ec 207-866-0 |
norfenchene |
3,6-endomethylenecyclohexene |
bicyclo(2.2.1)heptene |
einecs 207-866-0 |
8,9,10-trinorborn-2-ene |
bicyclo[2.2.1]hept-2-ene, 99% |
CHEBI:52286 |
AKOS005259230 |
2-norbornen |
(1r,4s)-bicyclo[2.2.1]hept-2-ene |
mfcd00082304 |
norbornene, 99% |
cis-norbornene |
norbornene 100 microg/ml in acetonitrile |
Excerpt | Reference | Relevance |
---|---|---|
"The toxic effect of strained hydrocarbon 2,2'-bis (bicyclo[2." | ( Genotoxic effect of 2,2'-bis(bicyclo[2.2.1] heptane) on bacterial cells. Bazhenov, S; Bermeshev, M; Gnuchikh, E; Kessenikh, A; Maksimov, A; Manukhov, I; Pevgov, V; Samoilov, V; Shorunov, S; Yaguzhinsky, L, 2020) | 0.56 |
Class | Description |
---|---|
bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
carbobicyclic compound | A bicyclic compound in which all the ring atoms are carbon. |
cyclic olefin | The inclusive term for any cyclic hydrocarbon having any number of double bonds. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.76) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |